GLUE monterosatx.com Net earnings per share growth forecast for next year

Corporate company logo of Monte Rosa Corp (GLUE)

The profit growth rate model for the coming year demonstrates a planned capital expenditure stage for research, with the value stabilizing at -71.30. Monte Rosa Therapeutics (GLUE) is automating the discovery of protein degraders through robotics. Financial stability is currently zero, as the company has no sales and relies entirely on external financing to develop its oncology projects.

GLUE: Monte Rosa Therapeutics Inc Net earnings per one share growth forecast for next year 07/04/2022 - 11/10/2026

Financial and market metric breakdowns for monterosatx.com (GLUE)

- share price and consensus valuation forecast:
Stock Price Monte Rosa Tx|GLUE - Analyst Consensus Forecast
- market capitalization data:
Market Value Monte Rosa Therapeutics|GLUE - Value Adjusted for Debt and Cash
- company book value details:
Book Value per Share Monte Rosa Therapeutics|GLUE - Book Value of Business|Market Capitalization to Book Value Ratio monterosatx.com|GLUE - Company Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Monte Rosa Therapeutics|GLUE - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Monte Rosa Therapeutics, Inc.|GLUE - Company Cumulative Debt|Debts to Book Capitalization Monte Rosa Therapeutics|GLUE - Company Long-Term Indebtedness|Company Current Liabilities Monte Rosa Therapeutics|Quick Liquidity Indicator monterosatx.com
- earnings and valuation multiples information:
GLUE - Profit After Payment of Taxes|Projected Future Earnings Monte Rosa Therapeutics|GLUE - Company Value to Net Income|Forward P/E Multiple Monte Rosa Therapeutics|GLUE - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Monte Rosa Therapeutics|GLUE - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Monte Rosa Therapeutics|GLUE - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months monterosatx.com|GLUE - Earnings per share trend in current year|Expected earnings per share growth for next year Monte Rosa Therapeutics
Fundamental company analysis:Monte Rosa Tx, GLUE
Brand item of monterosatx.com

Monte Rosa Therapeutics (GLUE) is developing oncology drugs, relying on partnership advances in the absence of its own operating leverage. This indicator reflects the expert consensus forecast for earnings per share changes, measuring future return potential. For a biotech company, this signals an upcoming commercial market entry and margin scalability. The non-retracing growth in the annual EPS forecast for Monte Rosa Therapeutics (GLUE) may indicate excessive optimism and a risk of correction.

Competing companies

GMAB (Genmab US) - Earnings growth forecast for next year|Earnings growth forecast for next year Exelixis Inc.|Net earnings per share growth forecast for next year Nuvalent, Inc. (NUVL)|KYMR (kymeratx.com) - Expected earnings per share trend next year|Earnings growth forecast for next year IDYA (IDEAYA Biosciences, Inc.)|Net earnings per one share growth forecast for next year Enliven Therapeutics Inc|ORIC Pharma - Earnings growth forecast for next year|Expected net earnings per share growth next year Relay Corp|NRIX (Nurix Therapeutics) - Expected earnings per share growth for next year|TYRA: Projected earnings per share increase next year|VSTM (Verastem) - Earnings growth forecast for next year|Expected net earnings per share growth next year Cullinan Oncology CGEM|Earnings growth forecast for next year IMRX|C4 Therapeutics Corp - Projected earnings per share growth rate for next year|Black Diamond - Expected earnings per share growth for next year|Expected earnings per share trend next year RPTX|PMVP: Expected earnings per share growth for next year|Karyopharm Therapeutics - Projected earnings per share increase next year|PPCB: Earnings growth forecast for next year|Cyclacel - Expected earnings per share trend next year|AADI (Aadi Bioscience Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year Aileron ALRN|Net earnings per share growth forecast for next year Blueprint Medicines (BPMC)|GLYC (glycomimetics.com) - Expected earnings per share trend next year|Earnings growth forecast for next year SWTX (SpringWorks)